Takeda Pharmaceutical Q3 Core EPS ¥150.00 Down From ¥168.00 YoY, Sales ¥1.11T Up From ¥1.096T YoY
Portfolio Pulse from Benzinga Newsdesk
Takeda Pharmaceutical reported a decrease in Q3 core EPS to ¥150.00 from ¥168.00 year-over-year, while sales increased to ¥1.11 trillion from ¥1.096 trillion. In USD terms, Q3 core EPS was $1.07, and sales were $7.885 billion.

February 01, 2024 | 6:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Takeda Pharmaceutical's Q3 earnings show a decrease in EPS but an increase in sales, indicating mixed financial performance.
The decrease in EPS may concern investors about profitability, while the increase in sales could be seen as a positive sign of growth. The mixed results create uncertainty, which typically leads to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100